Table 2.
Treatment-related adverse events.
| Adverse events | All grades | Grades 3-4 | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | p value | I2 | OR (95% CI) | p value | I2 | |
| Hematological | ||||||
| Leukopenia | 0.63 (0.49-0.81) | < 0.0001* | 40% | 0.28 (0.18-0.43) | < 0.0001* | 48% |
| Neutropenia | 0.58 (0.47-0.70) | < 0.0001* | 70% | 0.46 (0.38-0.56) | < 0.0001* | 55% |
| Anemia | 0.49 (0.41-0.60) | < 0.0001* | 34% | 0.47 (0.36-0.61) | < 0.0001* | 20% |
| Thrombocytopenia | 1.35 (1.09-1.68) | < 0.01* | 1% | 1.01 (0.71-1.44) | 0.97 | 0% |
| Febrile neutropenia | 0.58 (0.40-0.82) | < 0.01* | 65% | 0.58 (0.39-0.86) | < 0.01* | 67% |
| Non-hematological | ||||||
| Nausea | 0.63 (0.49-0.82) | < 0.0001* | 0% | 0.97 (0.55-1.71) | 0.92 | 15% |
| Vomiting | 0.78 (0.61-1.00) | 0.05 | 70% | 0.73 (0.31-1.71) | 0.47 | 11% |
| Stomatitis | 0.82 (0.68-0.98) | 0.03* | 1% | 1.86 (1.02-3.40) | 0.04* | 10% |
| Diarrhea | 1.33 (1.11-1.58) | < 0.01* | 89% | 1.94 (1.36-2.77) | <0.001* | 72% |
| Fatigue | 1.14 (0.88-1.49) | 0.31 | 76% | 1.64 (1.10-2.45) | 0.02* | 83% |
| Sensory neuropathy | 11.04 (8.91-13.67) | < 0.0001* | 70% | 9.16 (4.48-18.74) | < 0.0001* | 25% |
| Total bilirubin | 1.91 (1.38-2.63) | < 0.0001* | 40% | 1.74 (0.60-5.03) | 0.3 | 15% |
| AST | 5.29 (3.82-7.32) | < 0.0001* | 54% | 1.86 (0.68-5.09) | 0.23 | 26% |
| ALT | 2.22 (1.62-3.04) | < 0.0001* | 0% | 2.24 (0.77-6.52) | 0.14 | 44% |
| Creatinine | 0.16 (0.11-0.24) | < 0.0001* | 38% | 0.17 (0.03-0.99) | 0.05 | 0% |
| Thromboembolism | 0.42 (0.28-0.64) | < 0.0001* | 7% | NA | NA | NA |
OR, odds ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NA, not assessable. *p < 0.05, the difference is statistically significant.